Clinical Trials
28 trialsInterleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Interleukin-2 in Metastatic Kidney Cancer
Western Regional Medical Center
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Institutes of Health Clinical Center (CC)
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Vical
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
University of Chicago
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Endocyte
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau
ROSORC
Italian Trial in Medical Oncology
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
BZL Biologics